Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study Journal Article
| Authors: | Hensley, M. L.; Kravetz, S.; Jia, X.; Iasonos, A.; Tew, W.; Pereira, L.; Sabbatini, P.; Whalen, C.; Aghajanian, C. A.; Zarwan, C.; Berlin, S. |
| Article Title: | Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study |
| Abstract: | BACKGROUND: Eribulin mesylate is a tubulin inhibitor with activity superior to paclitaxel in NIH:OVCAR-3 human epithelial ovarian cancer xenograft models. In this study, the authors assessed the efficacy of eribulin in platinum-resistant and platinum-sensitive recurrent ovarian cancer. METHODS: Patients with recurrent, measurable epithelial ovarian cancer who had received ≤2 prior cytotoxic regimens and who had adequate organ function were enrolled into 2 separate cohorts: 1) platinum-resistant patients (who had a progression-free interval <6 months after their last platinum-based therapy) and 2) platinum-sensitive patients (who had a progression-free interval a 6 months after their last platinum-based therapy). Eribulin 1.4 mg/m;b was administered over 15 minutes intravenously on days 1 and 8 every 21 days. Efficacy was determined by objective response on computed tomography studies. RESULTS: In the platinum-resistant cohort, 37 patients enrolled, and 36 patients were evaluable for response and toxicity. Two patients achieved a partial response (5.5%), and 16 patients (44%) had stable disease as their best response. The median progression-free survival was 1.8 months (95% confidence interval, 1.4-2.8 months). In the platinum-sensitive cohort, 37 patients enrolled, and all were evaluable for response. Seven patients achieved a partial response (19%). The median progression-free survival was 4.1 months (95% confidence interval, 2.8-5.8 months). The major toxicity was grade 3 or 4 neutropenia (42% of platinum-resistant patients; 54% of platinum-sensitive patients). CONCLUSIONS: Eribulin produced an objective response in 5.5% of women with platinum-resistant, recurrent ovarian cancer and in 19% of women with platinum-sensitive disease. The median progression-free survival was 1.8 months in the platinum-resistant group and 4.1 months in the platinum-sensitive group. Copyright © 2011 American Cancer Society. |
| Keywords: | adult; cancer survival; clinical article; treatment response; aged; overall survival; neutropenia; cancer recurrence; cisplatin; cancer combination chemotherapy; diarrhea; drug efficacy; hypophosphatemia; side effect; treatment duration; gemcitabine; paclitaxel; topotecan; ovarian cancer; carboplatin; progression free survival; infection; ovary cancer; pain; anemia; leukopenia; clinical assessment; recurrence; docetaxel; febrile neutropenia; hyperglycemia; hypomagnesemia; lymphocytopenia; pneumonia; hypokalemia; hyponatremia; thrombosis; urinary tract infection; muscle weakness; platinum; ca 125 antigen; pemetrexed; ataxia; cytopenia; eribulin; phase 2 |
| Journal Title: | Cancer |
| Volume: | 118 |
| Issue: | 9 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2012-05-01 |
| Start Page: | 2403 |
| End Page: | 2410 |
| Language: | English |
| DOI: | 10.1002/cncr.26569 |
| PROVIDER: | scopus |
| PMCID: | PMC3245795 |
| PUBMED: | 21935916 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 4 June 2012" - "CODEN: CANCA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work